Gilead eyes takeover of cancer biotech Tizona, despite its t...

Gilead Sciences’ run of oncology-focused deals has continued with an option to buy cancer immunotherapy specialist Tizona – even though the biotech’s lead drug candidate is alr

FDA sets January action date for Keytruda in early bladder c...

Less than 4 Weeks until Immuno-Therapy Experts Gather at the...

Less than 4 Weeks until Immuno-Oncology Conference

The 4th Annual Oncolytic Virotherapy Summit - Boston 2018

Join the 4th Oncolytic Virotherapy Summit in Boston

Invitation from Chair of this year’s Immuno-Oncology Confere...

Invitation from Chair of Immuno-Oncology Conference

Avelumab filed, Pfizer and Merck prepare to join immunothera...

Checkpoint inhibitor drug set to be fourth competitor in PD-1/PD-L1 market